Obulytix joins BioVia to strengthen collaboration in the Belgian Life Sciences ecosystem

Obulytix is part of BioVia, the health innovation cluster for Flanders, bringing together companies, researchers, healthcare institutions, investors, and policymakers across the biotechnology and life sciences ecosystem.

As an industry-driven network connecting over 400 partners, BioVia plays an important role in fostering collaboration, accelerating innovation, and supporting the development of new health solutions—from early-stage research to market adoption.

Advancing collaboration in antimicrobial innovation

Antimicrobial resistance (AMR) remains a complex global health challenge. Obulytix develops Precision Lysin Therapeutics (PLTs), a new class of targeted biologics designed to address multidrug-resistant bacterial infections.

We believe that cutting-edge scientific innovation, combined with strong collaboration across research, industry, healthcare, and policy, is essential to translating scientific advances into real-world impact.

Strengthening connections across the ecosystem

Through its engagement with BioVia, Obulytix connects with a broad network of innovators, gains access to expertise and support, and contributes to initiatives that drive scientific and technological progress.

By remaining actively involved in this ecosystem, Obulytix aims to contribute to the continued growth of Belgium as a leading hub for biotechnology and life sciences, while advancing new approaches to tackle antimicrobial resistance.

For more information about BioVia, visit: https://www.biovia.be/